CFTR and cystic fibrosis: We also show that ASO-ψ works together with approved corrector and potentiator drugs to increase channel activity in cells from patients that are compound heterozygous for the splice mutation and the common F508del-CFTR mutation, thus broadening the treatment options and improving efficacy for CF patients with the CFTR c.3718-2477C>T mutation.